Legal capacities required for prevention and control of noncommunicable diseases

Roger S Magnusson, Benn McGrady, Lawrence Gostin, David Patterson & Hala Abou Taleb

Abstract Law lies at the centre of successful national strategies for prevention and control of noncommunicable diseases. By law we mean international agreements, national and subnational legislation, regulations and other executive instruments, and decisions of courts and tribunals. However, the vital role of law in global health development is often poorly understood, and eclipsed by other disciplines such as medicine, public health and economics. This paper identifies key areas of intersection between law and noncommunicable diseases, beginning with the role of law as a tool for implementing policies for prevention and control of leading risk factors. We identify actions that the World Health Organization and its partners could take to mobilize the legal workforce, strengthen legal capacity and support effective use of law at the national level. Legal and regulatory actions must move to the centre of national noncommunicable disease action plans. This requires high-level leadership from global and national leaders, enacting evidence-based legislation and building legal capacities.

Introduction

Noncommunicable diseases, including cardiovascular disease, cancer, respiratory diseases and diabetes, cause an estimated 41 million deaths each year. 1 Fifteen million of these deaths occur in people aged 30–69 years, 2 at a time of life when people are working and more likely to have dependants. Over 12 million (85%) of these premature deaths occur in low- and middle-income countries, where health systems may be fragile and access to treatments suboptimal. 3 So far, progress towards global goals (Box 1) and political commitments on noncommunicable diseases has been disappointing. 4 Unless urgent action is taken, the burden of mortality and disability from noncommunicable diseases will increase substantially, driven by population growth, longer life-expectancies and the global diffusion of risk factors such as tobacco use, harmful alcohol use, obesity, poor diet and sedentary lifestyles. 5

The effective use of law and regulation lies at the heart of successful national noncommunicable disease action plans. 6 Law includes international agreements, national and subnational legislation, subsidiary legislation (also known as regulations) and other executive instruments, and decisions of courts and tribunals. As a broader concept, regulation includes legislation, fiscal policies (such as taxes and subsidies) and other legally binding standards. Recognizing the power of law to improve the public’s health, the World Health Organization (WHO) offers technical assistance to governments on appropriate legal strategies (Box 2). Constraints and challenges in using law effectively at the national level include the lack of personnel with legal training or expertise, lack of resources for enforcement, and the influence of vested commercial interests in drafting, implementing and enforcing laws. Despite these challenges, law remains an important tool for taking action to reduce the burden of these diseases. Encouragingly, heads of state and governments have committed to promoting and implementing “policy, legislative, and regulatory measures, including fiscal measures” 7 to address noncommunicable disease risk factors and to developing legal expertise to integrate “public health-related legal issues into noncommunicable disease country support.” 8

This paper identifies some important areas of intersection between law and prevention and control of noncommunicable diseases, arguing that law lies at the centre of effective action. We suggest actions that WHO and other health development partners could take to strengthen national legal capacities and accelerate implementation of legal and regulatory strategies.

Law and noncommunicable diseases

Implementing preventive policies

In 2017, the World Health Assembly endorsed an updated set of policy options and cost-effective interventions for reducing the burden of noncommunicable diseases, including minimizing the major risk factors (consumption of tobacco, alcohol, unhealthy foods and drinks high in sugar). 9 Many of these recommended policies are legal interventions, requiring legislation or executive actions for effective implementation (Box 3). Sales of tobacco, alcohol, processed foods and sugar-sweetened drinks have expanded rapidly in low- and middle-income countries because of trade and investment liberalization, leading to greater foreign direct investment, imports and advertising. 9,10 Implementing WHO’s evidence-based, highly cost-effective policy interventions (called best-buys) should be a priority for governments, but requires political commitment, funding and strong legal capacity.

The force of law is needed to implement effective policies for prevention and control of noncommunicable disease risks because voluntary implementation will rarely be in the commercial interests of food, alcohol and tobacco companies. There are similarities in the ways these industries

---

1 Sydney Law School, University of Sydney, New South Wales, 2006, Australia.
2 Prevention of Noncommunicable Diseases Department, World Health Organization, Geneva, Switzerland.
3 WHO Collaborating Center for National & Global Health Law, Georgetown University, Washington, United States of America.
4 Health, Law and Development Consultants (HLDC), The Hague, Netherlands.
5 Health Systems Development Department, World Health Organization Regional Office for the Eastern Mediterranean, Cairo, Egypt.
Correspondence to Roger S Magnusson (email: roger.magnusson@sydney.edu.au).
Submitted: 15 July 2018 – Revised version received: 14 October 2018 – Accepted: 23 October 2018 – Published online: 20 November 2018.
seek to influence not only legislative outcomes, but also the perceptions of politicians and the public, the framing of issues for debate and the generation of favourable evidence. A growing literature illustrates the ways in which these industries, their allies and proxies, lobby governments, donate to political campaigns and undermine scientific evidence, seeking to shift the public focus from healthy public policies towards personal responsibility and fears of paternalism. Industry may also seek to pre-empt enforceable standards by implementing weaker, self-regulatory codes or may lobby to increase industry influence through partnerships and co-regulatory approaches. When regulating and dealing with these industries, governments and international institutions should implement rigorous conflict-of-interest policies to avoid inappropriate forms of influence.

Apart from seeking to reduce noncommunicable disease risk factors, law is an important tool for establishing institutional and governance mechanisms to support public health functions. For example, Samoa’s Health Promotion Act, enacted in 2013, established the Samoa Health Promotion Foundation, giving it a legislative mandate to engage in health promotion, fund research and advise the health minister. Through executive action, governments can also establish a national coordination mechanism to implement a whole-of-government approach to policy implementation that ensures policy coherence and mutual accountability of those ministries that have a bearing on noncommunicable disease risks. An example is Mexico’s National Council for the Prevention and Control of Chronic Noncommunicable Diseases, which brings together the heads of national executive agencies to coordinate cross-sectoral actions and policies. The WHO Independent High-level Commission on noncommunicable diseases has emphasized that action must start at the top, with the president or prime minister of a country leading a multisectoral national response.

**Constitutional rights**

The constitution of many countries guarantees health-related rights to their population. Constitutional rights not only limit parliamentary powers, but may permit individuals or groups to claim remedies for interference with their rights. In such countries, health-related rights may provide one avenue for challenging actions (and omissions) by governments and corporations that are harmful to health, as seen in India and Uganda (Box 4).

**Box 1. Global targets for reductions in noncommunicable disease risk factors**

**Global Monitoring Framework on noncommunicable diseases (World Health Organization)**

Overall target:
- by 2025, a 25% relative reduction in mortality from cardiovascular disease, cancer, diabetes and chronic respiratory diseases in persons aged 30–70 years.

Eight supporting targets:
- 10% relative reduction in harmful use of alcohol;
- 10% relative reduction in prevalence of physical inactivity;
- 30% relative reduction in mean average population salt intake;
- 30% relative reduction in prevalence of tobacco use (persons older than 15 years);
- 25% relative reduction in raised blood pressure;
- 0% increase in diabetes and obesity;
- 50% coverage for drug therapy and counselling for those at risk for cardiovascular disease;
- 80% coverage of affordable technologies and essential medicines for treating noncommunicable diseases in both public and private facilities.

**Sustainable development goal 3 (United Nations)**

Target 3.4:
- by 2030, reduce by one third premature mortality from noncommunicable diseases through prevention and treatment and promote mental health and wellbeing.

**Box 2. Scope of technical work on law and noncommunicable diseases by the World Health Organization**

The World Health Organization’s (WHO) work at the intersection of law and noncommunicable diseases includes:
- supporting governments to develop laws and regulations on health matters through technical assistance, training and provision of technical resources;
- comparative analysis of laws in different jurisdictions for WHO publications, including biannual reports on the global tobacco burden;
- analysing litigation and industry opposition to policies and laws, and integrating lessons learnt into technical assistance and resources;
- gathering evidence in support of effective public health laws and policies in Member States;
- providing assistance to Member States in litigation matters;
- intervening in legal disputes, for example, through the amicus briefs filed in disputes over tobacco control laws and;
- engaging with other inter-governmental organizations on legal and normative issues.

**International human rights**

International law can also influence national policies on noncommunicable disease prevention and control. For example, parties to the WHO Framework Convention on Tobacco Control have assumed an obligation under international law to implement policies on reduction in demand and supply of tobacco products. Most countries have also ratified at least one international agreement recognizing the right to health or other health-related rights. Such agreements include the WHO Constitution, various United Nations (UN) conventions (e.g. the Interna-
The right to health that are directly relevant to noncommunicable diseases. These include the obligation to ensure access to health services without discrimination; nutritionally adequate food; safe and potable water; and essential medicines. Under the Covenant, UN Member States also have an obligation to respect, protect and fulfil the right to health. The obligation to protect requires countries to prevent third parties, including corporations, from violating this right. Member States must also remedy regulatory failures, such as "failure to discourage production, marketing and consumption of tobacco, narcotics and other harmful substances." The obligation to fulfil the right to health addresses the problem of inaction by Member States, requiring them to adopt “legislative, administrative, budgetary, judicial, promotional and other measures” towards full realization of the right.

Each country’s compliance with its human rights obligations is reviewed through a process known as Universal Periodic Review, overseen by the UN Human Rights Council. Universal Periodic Review provides an impetus for governments to strengthen health-related rights, and may assist governments defending rights-based claims made by corporations, such as freedom of expression or property rights. During this process, human rights treaty bodies may draw attention to priority risk factors, urging Member States to implement effective policies on noncommunicable diseases. For example, concerned about increasing food insecurity (including its link with obesity) and low levels of breastfeeding, the Committee urged the United Kingdom of Great Britain and Northern Ireland to implement national policies on breastfeeding in accordance with World Health Assembly resolutions and the International Code of Marketing of Breast-milk Substitutes; increase taxes on unhealthy foods and sugar-sweetened drinks; and “consider adopting strict regulations on the marketing of such products, while ensuring improved access to healthy diets.”

Similarly, in 2014, the Committee expressed concern about tobacco addiction in Indonesia, recommending indoor smoking bans in public buildings and workplaces, and a ban on tobacco advertising and sponsorship. In 2007, the Committee on the Rights of the Child recommended that Chile “take necessary measures to reduce and prevent the incidence of obesity among children.” This report could strengthen Chile’s position in countering litigation initiated by food producers against the country’s restrictions on marketing to children.

International human rights law and practice is a neglected resource for governments seeking to reduce the burden of noncommunicable diseases. Analysis of specific health rights within international human rights agreements provides important guidance in many areas, such as tobacco control and marketing of foods and beverages. International treaty bodies could make greater use of the WHO Framework Convention on Tobacco Control and authoritative sources of guidance on risk factors, including the Global Ac-
Trade and investment agreements

International trade law is another important area of law that impacts on risk factors for noncommunicable diseases. International trade and investment agreements can affect noncommunicable disease risk factors in complex ways; for example, by reducing prices, increasing competition, and facilitating international trade and investment in harmful products, such as tobacco and alcohol.7

In legal terms, trade and investment agreements discipline how states can regulate. For example, World Trade Organization (WTO) law establishes core principles of trade law, including prohibiting discriminatory regulation, requiring that regulation be not more trade restrictive than necessary to protect health, and requiring minimum standards of protection for intellectual property rights. The WTO panels have applied these principles in adjudicating legal disputes concerning tobacco control. For example, a WTO panel held that United States legislation banning menthol-flavoured tobacco, but exempting menthol-flavoured products discriminated in favour of domestic products.36 More recently, a WTO panel upheld Australia’s tobacco plain packaging laws as not more trade restrictive than necessary and not an unjustifiable encumbrance on the use of trademarks.7 WTO committees have also discussed legal measures to reduce harmful alcohol use17 and improve healthy diets,36 although such measures have not resulted in WTO disputes.

Regional trade agreements are increasingly important. Customs unions, such as the European Union, can lead to harmonization of laws, such as through the 2014 European Tobacco Products Directive.39 However, rules concerning free movement of goods, state aid and communications can also be used to challenge fiscal and regulatory measures. Examples include the (recent unsuccessful) challenge to the introduction of minimum unit pricing on alcoholic beverages in Scotland,40 limitations on Sweden’s ability to restrict alcohol marketing originating in the United Kingdom,41 and the scraping of a Finnish confectionary tax because of rules concerning state aid.42

Investment treaties, whether bilateral or as investment chapters in trade agreements, can also impact on legislation concerning noncommunicable diseases. The tobacco company Philip Morris International recently challenged tobacco control laws in Australia and Uruguay. These claims, which were unsuccessful but expensive to defend, concerned plain tobacco packaging, health warnings and other labelling requirements implemented in response to the WHO Framework Convention on Tobacco Control.6,8

Litigation and complaints mechanisms

Challenges to policies for prevention and control of noncommunicable diseases are frequently resolved in national courts and tribunals, as illustrated again by the alcohol industry’s 5-year attempt to overturn Scotland’s legislation on minimum alcohol pricing.53 The tobacco, food and alcohol industries are increasingly suing governments, relying on constitutional and human rights guarantees, although with mixed success.44

On the other hand, litigation and use of other complaints mechanisms can be used to hold industry to account for harm caused by their products, to improve access to medicines and to vindicate other health-related rights.5

Tobacco litigation in the United States has had a major impact. A Department of Justice lawsuit found that for half a century the tobacco industry engaged in a pattern of fraudulent conduct to deceive the American public about the effects of cigarettes on health.45 Complaints made under consumer protection laws are another underused tool. For example, an Australian court imposed a fine of more than 2 million Australian dollars against the Heinz food company for engaging in false and misleading conduct by advertising that a chewy fruit snack, containing about...
two-thirds sugar, was beneficial to the health of children aged 1–3 years.46

Effective use of law

Legislation and executive actions are essential for noncommunicable disease prevention and control, while many of the challenges to effective national plans, such as defending litigation initiated by industry, also call for technical legal expertise. However, governments face major obstacles to using law effectively, including lack of trained personnel, lobbying by powerful industry groups and uncertainty about the extent of their country’s obligations under trade and investment agreements.44 Nevertheless, as Box 5 illustrates, governments can overcome these challenges and pass innovative laws for prevention and control of noncommunicable disease risk factors.

Public health advocates have called on the World Health Assembly to make bold use of its legal powers, through a convention on alcoholic beverages56 or obesity57 and unhealthy diets. A global coordinating agency for noncommunicable diseases has also been proposed, to encourage public and private financing, aligned with the sustainable development goals.48 However, even in the absence of these major reforms, we see opportunities for governments and their development partners, including WHO, to strengthen national noncommunicable disease prevention and control.

Sharing good practices

The WHO Independent High-level Commission on noncommunicable diseases encouraged governments to use their “full legal and fiscal powers to achieve public health goals.”49 This includes regulating harmful products and practices, and strengthening the institutions, functions and official roles that are needed to ensure compliance with legal standards.50 Effective use of law requires budgetary resources for enforcement, including training. Distinct from its law-making role, WHO’s power to develop soft (non-binding) normative standards, together with its capacity to convene and disseminate expert knowledge, remain powerful tools. WHO is already developing technical resources to support regulatory actions by governments; for example, implementing plain packaging of tobacco products50 and the International Code of Marketing of Breast-milk Substitutes.46 WHO, with its development partners, should invest further to increase technical resources in law and regulation.

WHO could also facilitate the diffusion of policy across Member States by creating opportunities for governments that are leading the way to share their practical experiences of drafting, implementing and enforcing laws and fiscal policies.58 Since legal systems vary widely, such exchanges among officials and stakeholders in different countries are likely to be more productive than exhaustively cataloguing health laws or promoting model legislation. Recent experience with plain packaging of tobacco products shows that technical activities such as training workshops, online platforms linking people who work in a common field and comparative analysis of laws and litigation can also facilitate policy diffusion.

Mobilizing the legal workforce

Building legal capacity means mobilizing a workforce with the technical skills to navigate legal issues arising in key areas of noncommunicable disease prevention and control.41 Such efforts could help to translate evidence and WHO guidance into country-level action. Creating a platform for lawyers, legislators, educators and public health experts to interact may not only improve the exchange of advice and information across governments, civil-society organizations and academia, but also provide mentors for young leaders working on reform of laws on noncommunicable diseases in low-resource countries.

Leadership requires greater investment in legal capacity within WHO and other agencies working in health development, and careful assembling of a legal workforce. Donor funding for a dedicated public health law programme within WHO to support countries in implementing best-buy policy interventions could have a substantial impact.59 Within available resources, we see two key areas where global leadership could strengthen legal capacities.

First, WHO could facilitate professional exchanges and mutual support among those who use legal knowledge in key practice areas. Fostering such a transnational network could be achieved
require a national response, state, city noncommunicable diseases ideally although prevention and control of tobacco industry strategies. 63 No comparable resource exists for taking action on unhealthy diets or harmful use of alcohol. Consequently, industry legal arguments are neither systematically tracked nor easily anticipated.

Building on local innovations

Although prevention and control of noncommunicable diseases ideally require a national response, state, city and local governments can be powerful innovators (Table 1). Unlike national governments, smaller, defined localities often have more homogeneous constituencies, smaller and more efficient administrative systems and less time-consuming legislative processes. In response to political activism, social mobilization and specific social, economic and demographic factors, local and city administrations can become laboratories for innovation, trialling new legal approaches. The impact of these local innovations can be evaluated, disseminated and implemented both horizontally (to other localities) and vertically (at state and national levels). 64

Local governments have been leaders in many areas of noncommunicable disease policy. In the United States, local jurisdictions were the first to impose higher taxes, marketing restrictions and bans on smoking in public places, among other interventions. 65 Some cities and towns have adopted a range of additional strategies, such as banning trans-fatty acids from the food supply, raising the minimum purchasing age for tobacco products and imposing health-based taxes on sugar-sweetened drinks. 66

Coordinating regional action

Regionally coordinated action can accelerate the implementation of legislation, particularly by smaller countries. The best opportunities exist in regions that have a strong history of cooperative action. WHO’s regional offices and other regional political groupings (e.g. the Pacific Community, the Caribbean Community, the African Union, the Association of Southeast Asian Nations or the Organization of American States) could lead, coordinate and support national noncommunicable disease policies. Deliberate, planned, regional action could benefit small, remote and vulnerable populations whose governments may otherwise engage in prevention and control in a piecemeal fashion and at a slower rate. Regional action allows more efficient use of legal resources, although careful groundwork is needed to create a shared vision and agreed principles for action. Box 6 summarizes an example from WHO’s Regional Office for the Eastern Mediterranean.

Table 1. Examples of local innovations in prevention and control of noncommunicable diseases in the United States of America

| Policy innovation and example | Description | Reference |
|------------------------------|-------------|-----------|
| Information disclosure       | Restaurant chains and food retailers in New York city must disclose calorie counts on menu boards for standard menu items | New York City Health Code §4203(a) (2017) |
| Soda warning rule            | Billboards advertising sugar-sweetened drinks in San Francisco city must contain a health warning about the impact of added sugars on obesity, diabetes and tooth decay | San Francisco Health Code art. 4.2 (2006) |
| Haemoglobin A1C registry      | New York city’s health code makes glycated haemoglobin (a measure of blood sugar control) a reportable condition by pathology laboratories. The registry helps to identify patients with poorly controlled diabetes or who need follow-up care | New York City Health Code §13.07 (2006) |
| Marketing restrictions       | Maine was the first state to prohibit brand-specific advertising of food or beverages in school buildings or on school grounds | Title 20-A Maine Rev. Stat. Ann §6662 (2007) |
| Taxation                     | Fast-food restaurants in San Francisco city are prohibited from providing free toys in children’s meals | San Francisco Health Code art. 8 §471.1 to 471.9 (2011) |
| Sugar-sweetened beverage tax | The city of Berkeley was the first jurisdiction in the country to impose an excise tax of 1 cent per ounce on sugar-sweetened drinks | Berkeley Municipal Code Chapter 7.72 (2014) |
| Sugar-sweetened beverage tax | Philadelphia was the first major city to levy a tax of 1.5 cents per ounce on sugar-sweetened drinks and to earmark tax revenue for improvements to parks, libraries and recreation centres | Philadelphia Code §§19–4101 to 4108 (2016) |
| Built environment: zoning   | California State’s Urban Agriculture Incentive Zones Act reduces property taxes for landowners who enter a contract to permit small-scale agriculture or animal husbandry for at least 5 years on vacant lands | Cal Govt Code §51042 (2017) |
| Ordinance to control prevalence of fast-food outlets | The city of Los Angeles limits new fast-food restaurants in areas with an over-concentration of fast-food outlets | L.A. Cal. Ordinance 180103 (2008) |

§: section; §§: sections.
Policy & practice
Law and noncommunicable diseases

Roger S Magnusson et al.

Box 6. Example of effective and regionally relevant legal interventions for control of noncommunicable diseases by WHO

The World Health Organization Regional Office for the Eastern Mediterranean (WHO-EMRO), partnered with the O’Neill Institute for National and Global Health Law at Georgetown University, Washington, United States of America, to spur legal reform for noncommunicable disease prevention and control. The project identified affordable, feasible and cost–effective legislative and regulatory interventions that were suitable for implementation in the Eastern Mediterranean Region.

The comprehensive dashboard of legal interventions proposed that WHO-EMRO Member States prioritize interventions in three key domains: (i) noncommunicable disease governance mechanisms requiring multisectoral collaboration, accountability and transparency; (ii) tobacco control laws in compliance with the WHO Framework Convention on Tobacco Control;27 and (iii) laws to promote healthier diets, such as reducing consumption of sodium and sugar.28 WHO-EMRO committed to support Member States to enact and enforce population health improvements through these priority interventions. The project includes implementation guidance tools as well as capacity-building initiatives led by multidisciplinary teams of legislators and public health experts.29 The O’Neill Institute partnered with WHO-EMRO to produce a detailed description of the evidence-based legal interventions to reduce noncommunicable disease prevalence in the Region.30

Conclusion

Legislative and regulatory actions lie at the heart of successful national and local strategies for noncommunicable disease prevention and control. However, the role of law as a public policy tool, translating scientific evidence and normative guidance into action, receives inadequate attention amid the dominance of other disciplines in global health development. This needs to change. Rapid progress in tobacco control has not been accidental, but reflects agreement about the critical importance of law to tobacco control – leading, in turn, to adoption of strong, legally-binding standards at international and national levels. The rapid progress also reflects global investment in capacity-building, technical assistance to WHO Member States, and expansion of legal resources, assisted by organizations such as Bloomberg Philanthropies and the Bill & Melinda Gates Foundation. These factors, which have accelerated progress in tobacco control, are not yet present for other noncommunicable disease risk factors such as unhealthy diets and harmful use of alcohol. Legal and regulatory action must move to the centre of national noncommunicable disease action plans. This requires high-level leadership at local and national levels, developing evidence-based legislation through transparent processes, enforcing it, evaluating its effectiveness and building legal capacities.

Acknowledgements

We thank Sibel Ozcelik, Han-Hsi Liu and Jingyi Xu.

Competing interests: None declared.

ملخص

الصلاحات القانونية الطالبة للوقاية من الأمراض غير المعدية ومكافحتها

يتعلق القوانين حجر الزاوية بالنسبة للإجراءات الوقائية والتشريعات الطبية، وتشكل قاعدة العمل الوطنية للأمراض غير المعدية. وتعطى تلك قاعدة عامة المستوي من القادة العامين والوطنيين ومساندتها قياسية على الأدلة وبناء الصلاحات القانونية.

Summary

Preventive and control for non-communicable disease-related law capacity

Law is a critical determinant of the control of infectious diseases. It is essentially about the development of evidence-based laws, guidelines, and regulations that are enforceable and sustainable. These laws and regulations are developed through a process of evidence-based analysis, policy development, and legislative and regulatory action. The laws are then enforced through the legal system, including courts and tribunals, to ensure compliance with the law.

In turn, this leads to adoption of strong, legally-binding standards at national and international levels. The rapid progress also reflects global investment in capacity-building, technical assistance to WHO Member States, and expansion of legal resources, assisted by organizations such as Bloomberg Philanthropies and the Bill & Melinda Gates Foundation. These factors, which have accelerated progress in tobacco control, are not yet present for other noncommunicable disease risk factors such as unhealthy diets and harmful use of alcohol. Legal and regulatory action must move to the centre of national noncommunicable disease action plans. This requires high-level leadership at local and national levels, developing evidence-based legislation through transparent processes, enforcing it, evaluating its effectiveness and building legal capacities.
Résumé
Capacités juridiques requises pour prévenir et maîtriser les maladies non transmissibles
Le droit est au cœur des stratégies nationales efficaces de lutte contre les maladies non transmissibles. Par droit, nous entenndons les accords internationaux, les législations nationales et infranationales, les réglementations et autres instruments exécutifs, et les décisions des cours et des tribunaux. Cependant, le rôle vital du droit dans le développement de la santé à l’échelle mondiale est souvent mal compris, et éclipsé par d’autres disciplines telles que la médecine, la santé publique et l’économie. Cet article définit des domaines d’intersection clés entre le droit et les maladies non transmissibles, en commençant par le rôle du droit en tant qu’outil pour mettre en œuvre des politiques visant à prévenir et maîtriser les principaux facteurs de risque. Nous mettons en évidence des mesures que l’Organisation mondiale de la Santé et ses partenaires pourraient prendre pour mobiliser les professionnels du droit, renforcer les capacités juridiques et soutenir une utilisation efficace du droit au niveau national. Des mesures juridiques et réglementaires doivent être placées au centre des plans d’action nationaux pour la lutte contre les maladies non transmissibles. Cela nécessite un leadership de haut niveau de la part des dirigeants internationaux et nationaux, à travers l’adoption de lois et de règlements fondés sur des données scientifiques et un renforcement des capacités juridiques.

Resumen
Fortalecer la capacidad jurídica para la prevención y el control de las enfermedades no contagiosas
La ley es la clave del éxito de las estrategias nacionales para la prevención y el control de las enfermedades no contagiosas. Por ley entendemos los acuerdos internacionales, la legislación nacional y subnacional, los reglamentos y otros instrumentos ejecutivos, así como las decisiones de los tribunales y las cortes de justicia. Sin embargo, el papel vital de la ley en el desarrollo de la salud mundial a menudo no se comprende bien y se ve eclipsado por otras disciplinas como la medicina, la salud pública y la economía. Este documento identifica las áreas clave de intersección entre la ley y las enfermedades no contagiosas, empezando por el papel de la ley como herramienta para implementar políticas de prevención y control de los principales factores de riesgo. Se determinan las medidas que la Organización Mundial de la Salud y sus asociados podrían adoptar para movilizar al personal legal, fortalecer la capacidad jurídica y apoyar el uso eficaz de la legislación a nivel nacional. Las acciones legales y reglamentarias deben pasar a ser el centro de los planes de acción nacionales para las enfermedades no contagiosas. Esto requiere un liderazgo de alto nivel por parte de los líderes mundiales y nacionales, para promulgar una legislación basada en pruebas y crear capacidades jurídicas.

References
1. Noncommunicable diseases. Fact sheet [internet]. Geneva: World Health Organization; 2018. Available from: http://www.who.int/ncds/management/time-to-deliver/
2. Global action plan for the prevention and control of noncommunicable diseases 2013–2020. Geneva: World Health Organization; 2013.
3. Transforming our world: the 2030 agenda for sustainable development. A/RES/70/1. 21 October 2015. New York: United Nations General Assembly; 2015.
4. Time to deliver. Report of the WHO Independent High-level Commission on Noncommunicable Diseases. Geneva: World Health Organization; 2018. Available from: http://www.who.int/nmh/dossiers/time-to-deliver/en/ [cited 2018 Oct 11].
5. Rethinking development and health: findings from the Global Burden of Disease Study. Seattle: Institute for Health Metrics and Evaluation; 2016. p. 60.
6. Advancing the right to health: the vital role of law. Geneva: World Health Organization; 2017. Available from: http://www.who.int/healthsystems/topics/health-law/health_law-report/en/ [cited 2018 Oct 11].
7. Dispute settlement: Australia – certain measures concerning trademarks, geographical indications and other plain packaging requirements applicable to tobacco products and packaging. WT/DS435/R, WT/DS441/R, WT/DS458/R, WT/DS467/R. Geneva: World Trade Organization; 2018. Available from: https://www.wto.org/english/news_e/news18_e/435_441_458_467_e.htm [cited 2018 Oct 11].
8. Philip Morris Asia Ltd (Hong Kong) v The Commonwealth of Australia, Award on Jurisdiction and Admissibility, PCA Case No. 2012-12. The Hague: Permanent Court of Arbitration; 2015. Available from: http://www.pca-cases.com/web/view/5 [cited 2018 Oct 11].
9. Philip Morris Brands Sàrl & Others v Oriental Republic of Uruguay, Award, ICSID Case No. Arb/10/7. Italaw; 2018. Available from: https://www.italaw.com/cases/460 [cited 2018 Oct 11].
